Back to Stakeholders
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchIndependent Academic Research Groups
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & Manufacturing

EmpathBio, Inc.

United States
1 Trial

EmpathBio Inc. is an ATAI Life Sciences subsidiary developing EMP-01, an MDMA derivative designed to preserve entactogenic therapeutic properties while reducing cardiovascular and stimulant side effects, with PTSD as the primary indication. The company completed a Phase 1 trial of EMP-01 in 32 healthy volunteers in New Zealand.

Academic Research

0 papers

Published Papers

0

Trial Involvement

1

Distinct Focus Topics

0

Latest Publication

Unknown

Quick Facts

Type
Subsidiary
HQ
United States
Website
Visit

Collaborated Trials

1
CompletedII

Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder

Start Date
Compounds
Placebo